National Health Laboratory Service / Enterprise Africa by CMB Media Group

NATIONAL HEALTH LABORATORY SERVICE

Underpinning SA’s Healthcare

Through Toughest Times PRODUCTION: Karl Pietersen

The NHLS has been at the forefront of the battle against Covid-19, providing countrywide testing solutions while maintaining its first-class national pathology service. This is a business achieving its vision and serving the country with excellence and sustainability. CEO Karmani Chetty tells Enterprise Africa more about the development of this exciting healthcare heavyweight. www.enterprise-africa.net / 3

INDUSTRY FOCUS: HEALTHCARE

South Africa’s National Health Laboratory Service (NHLS) is the central provider of health laboratory services, education and research. Its mission is to ‘provide pathology and laboratory services through competent professionals and state-of-the-art technology, supported by evidence-based research, training, and innovation to enhance integrated service delivery to meet the needs of the population’. Its national network of laboratories provides medical testing capabilities which allow doctors to provide the best possible treatment for those in need. Already serving 80% of the population, the NHLS utilises its subsidiaries to provide a range of vital services that protect and better the lives of South Africans. The National Institute for Communicable Diseases (NICD), National Institute for Occupational Health (NIOH), Forensic

4 / www.enterprise-africa.net

Chemistry Laboratories (FCL) and the South African Vaccine Producers (SAVP) all fall under the NHLS umbrella. At the start of 2020, provision of medical testing was thrust into the spotlight as the Covid-19 pandemic ripped through the world. In South Africa, tough measures put in place to curb the spread of the virus, and the NHLS was asked to step up like never before. “It was certainly challenging in many ways, it also showed how strong we are as an organisation – even in the toughest of times,” CEO Karmani Chetty tells Enterprise Africa. COVID-19 CHALLENGE Traditionally, the NHLS core service surrounded pathology. In South Africa, where illnesses including cancer, HIV and AIDS, diabetes, TB, asthma, and others remain underdiagnosed and undertreated,

the healthcare environment is already challenged. But the onset of Covid-19 saw the goalposts moved with the NHLS tasked with the continuation of industry-leading pathology and related services while developing a country-wide testing strategy at the same time as advising government on many associated issues including local vaccine

// IT WAS CERTAINLY CHALLENGING IN MANY WAYS, IT ALSO SHOWED HOW STRONG WE ARE AS AN ORGANISATION – EVEN IN THE TOUGHEST OF TIMES //

NATIONAL HEALTH LABORATORY SERVICE

development and deployment policy. For every business and every individual, it was a time fraught with trials and uncertainties. The NHLS endured and assisted the country in its movement through the pandemic without faltering. “We had challenges in getting test kits due to a global shortage of polymerase chain reaction (PCR) and extraction kits, logistical issues (such as interruptions with production), flights cancellations, customs delays, and closure of services during public holidays,” details Chetty, a seasoned business leader and medical doctor with expertise across many other spheres. “These and other challenges led to testing backlogs in the laboratories and increased turnaround time of results. This was compounded by the unavailability of staff due to Covid-19 infections and Covid-19 lockdown and social distancing regulations.”

Always working hard to ensure testing and delivery of results was as efficient as possible, the NHLS diversified its PCR and extraction platforms, implementing a testing strategy which prioritised those with a medical need and for clinical diagnosis, for example, suspected symptomatic Covid-19 cases and clinical diagnosis for patients with respiratory diseases at health care services. The company also decentralised testing to district laboratories and mobile laboratories by using GeneXpert instruments when the test kits became available. The GeneXpert system requires minimal human input and less infrastructure or equipment, making for a more efficient process. “The organisation had 128 Covid-19 testing laboratories, including the mobile laboratories, by the end of the 2020/21 financial year. Despite these challenges, we were still able

to conduct over four million Covid-19 tests by the end of the financial year with an average turnaround time of 48 hours,” says Chetty. The CEO is understandably proud of the role the company has played in the ongoing battle against Covid-19 and its success of continuing to deliver primary services throughout. The NHLS runs two hotlines for doctors and the public as well as an emergency operating centre and this have been maintained throughout a challenging period. “The pandemic has forced the adoption of new ways of working,” admits Chetty. “Like many other organisations in South Africa and around the world, we have risen to the occasion by expeditiously put measures in place to safeguard our employees and instituted a new way of working as per our business continuity plan. We put

www.enterprise-africa.net / 5

INDUSTRY FOCUS: HEALTHCARE

many our employees on rotation, especially those working in areas where adhering to social distancing protocols would have been impossible. We also made sure that those working from home have all the right tools of the trade - most importantly, connectivity. As such, we have embraced agility and adaptability to ensure that we remain at the forefront of delivering quality

testing for Covid-19 in the fight against the spread of the pandemic in South Africa.” Across the country, the NHLS and its subsidiaries employ more than 8000 dedicated people in all nine provinces, described by Chetty as “very committed, working long hours”. Not a simple off the shelf product, the offering from the NHLS has been carefully developed over a long

period of time and is continuously monitored and adapted to suit the needs of the time. By growing from two to 128 Covid testing labs and generating R1.9 billion between 1 April 2020 and 31 March 2021, the business remained structurally and financially solid.

Continues on page 8

SA PATHOLOGY – PUTTING THE PATIENT FIRST InterSystems supports the NHLS with an advanced and proven laboratory application delivering the best possible care to patients across South Africa. The journey to improved pathology services and overall healthcare service delivery was started by the National Health Laboratory Service (NHLS) in 2008 when the organisation purchased TrakCare Lab, a world class laboratory application from global technology company InterSystems. Today the NHLS handles all public health sector pathology testing and provides an extensive array of research and disease monitoring services that support the over 3,800 clinics and more than 400 hospitals in the South African public healthcare system. A division of the National Department of Health, the NHLS’ system is a vital factor in the delivery of healthcare services for the approximately 50 million uninsured South Africans. The growing pressure of conditions such as Covid-19, in addition to TB and HIV, have seen new demands placed on the NHLS and as a result, within the TrakCare Lab environment, the NHLS processes around 500,000 tests from 150,000 lab requests each day. “Pathology is a vital component of clinical care delivery, as blood tests are the key medical practitioners need to unlocking a diagnosis. This means blood tests needs to be processed quickly and accurately,” says Henry Adams, Country Sales Manager at InterSystems. “With TrakCare Lab, the NHLS has benefited from a system that allows a practitioner to place an order for a test, the NHLS completes the analysis and provides a report back to the clinician to complete his diagnosis of the patient. Reports are available digitally, and up to 15,000 medical professions can view these at the same time,” details Adams. TrakCare Lab has been an obvious choice for the NHLS. The software has not only been widely successful in helping the NHLS meet its goals, but, as it is also used in over 25 countries globally, this multi-layered software application with database interoperability incorporates global best practices. “The NHLS can provide quick turnaround times when processing blood tests at scale because of InterSystems’ technology. TrakCare Lab is deployed as a central installation and accessed by all the NHLS labs. This means the NHLS enjoys an average cost per test that is very low compared to international benchmarks,” says Adams. The TrakCare Lab application at the NHLS paves the way for a connected healthcare system that facilitates patientcentred care. The partnership between InterSystems and the NHLS is a perfect example of two industry leaders coming together to solve real problems that impact the lives of South Africans. InterSystems partners with global healthcare providers and governments across multiple disciplines, delivering innovative data solutions for their critical information needs. It provides the world’s most proven electronic medical and unified care records system and supports data management with a powerful suite of healthcare data integration solutions. Beyond healthcare, its cloud-first data platforms solve interoperability, speed, and scalability problems in healthcare, finance, and amongst others, logistics.

6 / www.enterprise-africa.net

BEING HELD BACK BY THE LIMITS OF YOUR LIMS? Need to review operational performance, plan more effectively and make more informed decisions?

You need TrakCare Lab Enterprise – so much more than just a LIMS

Learn more at: InterSystems.com/UK/TCLE

INDUSTRY FOCUS: HEALTHCARE

Continued from page 6 HISTORIC IMPORTANCE Established in 2001, the NHLS is overseen by the Department of Health and is a leader on the continent in terms of the research and training delivered. “Our activities comprise diagnostic laboratory services, research, teaching and training, and production of sera for anti-snake and other venom, reagents and media,” confirms Chetty. “The NHLS is unique in that it is the only state diagnostic laboratory. It is also the largest diagnostic pathology service in South Africa, with a network of approximately 233 pathology laboratories and providing different tests in all pathology disciplines. We are in formal partnership with South Africa’s universities, and our staff teach and provide practical training for every single medical, allied health professional and medical technology student, every trainee-specialist in pathology, as well as many scientists.” Meeting the needs of the population by providing healthcare and protection, the NHLS subsidiary - the SAVP - produces antivenoms for the treatment of bites from eleven of the most medically important snakes prevalent in southern and other parts of Africa, as well as for spider bites

// TECHNOLOGY IS ADVANCING AT A RAPID PACE AND WE NEED TO BE ABLE TO SPEEDILY RESPOND TO SUCH CHANGES THROUGH HOW WE STRUCTURE AND DELIVER OUR SERVICES // 8 / www.enterprise-africa.net

and scorpion stings. In South Africa, button spiders, baboon spiders, violin spiders, sac spiders and more have the ability to cause serious harm. Venomous snakes kill around 30,000 people every year in sub-Saharan Africa (recorded deaths) with the bush viper, water cobra, African mambas and others particularly lethal. The SAVP is the country’s sole producer of effective and researched antivenom and provides quality products for use when they are sorely needed. “We also have an in-house diagnostic media manufacturing arm, Diagnostic Media Products (DMP), which manufactures and supply a wide range of high-quality diagnostic reagents, ready to use kits, and microbiological culture media,” says Chetty of the group’s portfolio. “DMP’s products range from routine microbiological media to more specialised media for dedicated laboratories such as food microbiological media and environmental testing media to a wide range of stains used in microbiology and manufacture viral transport media and phosphate-buffered saline used in hospital laboratories and at private clinical laboratories for the collection and transport of samples for molecular RT-PCR SARS-CoV-2 assays.” In addition, further signifying the importance and impact of the

business, Chetty highlights 67 mobile units deployed in high population density areas, rural areas, and informal settlements to enable testing for Covid-19 for those members of the public who do not have access or means to visit local clinics and/or designated testing sites. The mobile units have also been utilised at border posts for testing. Clearly, the range of services and the positive effect of the portfolio is a true asset to South Africa and the wider African community. MODERNISING In 2013, the NHLS picked up a Business Initiative Directions (BID) International Stars Award for quality. This was after, in 2012, two NHLS researchers played a major role in research that took us closer to a HIV vaccine. And in 2008, the company launched TrakCare – a standardised laboratory information system – from InterSystems to provide efficiency across its technology systems. Without doubt, the NHLS is forward thinking and regularly displays its ambitions around pushing the cutting edge while continually breaking boundaries. Whether this is through new systems in partnership with industry leaders like InterSystems, or internally across the entire human resource, the NHLS is actively modernising.

NATIONAL HEALTH LABORATORY SERVICE

// WE HAVE EMBRACED AGILITY AND ADAPTABILITY TO ENSURE THAT WE REMAIN AT THE FOREFRONT OF DELIVERING QUALITY TESTING FOR COVID-19 IN THE FIGHT AGAINST THE SPREAD OF THE PANDEMIC IN SOUTH AFRICA // “Technology is advancing at a rapid pace and we need to be able to speedily respond to such changes through how we structure and deliver our services. As such, we are making a major investment in our IT infrastructure to enable higher quality healthcare in support of patients through new and improved system deployments, which incorporate numerous applications across different interfaces,” explains Chetty. Henry Adams, Country Sales Manager at InterSystems adds: “It is a Laboratory Information System (LIS). In the public space, 85% of test

requests are still handled manually. Today, there are around 130,000 test requests per day. Each test request has on average 4.5 individual tests. Still, most of these are captured manually. Our system takes all the test requests and processes the requests by sending requests to an analyser and then returning the results. We control the analysers and we verify the results, and depending on the nature of the test, we create a detailed pathology report. We print around 500,000 pathology reports each day but we also make all results available digitally for viewing by up to 15,000 people at

any time. The result is a direct impact on quality of care that a doctor gives to a patient.” This expansion on the TrakCare system will be welcomed by the NHLS team who themselves have been the target of a modernisation and development programme. Especially under the spotlight right now is gender equality within the business – the same as all stateowned enterprises. The NHLS has a good history after its Professor Valerie Mizrahi was voted Women of the Year in Health, Science and Technology in 2006 at the Checkers/SABC 2 Awards.

THIS DRIVES YOU

AUTOMATED LABORATORIES DRIVE US WHAT DRIVES YOU? At Beckman Coulter, we believe you got into healthcare because you’re motivated to help elevate patient care. But we know sometimes that’s hard to do. Increasing demands. Decreasing budgets. Faster turnaround times. It can all weigh you down. That’s why we’re creating workflow and automation solutions to help drive your laboratory further and faster, so you can discover the freedom to level-up your laboratory.

Learn how automation can drive your motivation. © 2020 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. For Beckman Coulter’s worldwide office locations and phone numbers, please visit www.beckmancoulter.com/contact

www.enterprise-africa.net / 9

INDUSTRY FOCUS: HEALTHCARE

“We are committed to fostering an inclusive environment where everyone can succeed. The links between gender diversity and organisational success are well documented and we have many talented women at NHLS who are experts and leaders in their fields,” says Chetty.

“As such, the representation of women occupying top management positions at NHLS stands at 57%, while 61% accounts for women in senior management.” In total, female representation in the business stands at 68.2% with majority percentages holding professional qualifications, and skilled

and semi-skilled labour positions. According to Chetty, progress towards gender parity remains a top priority and current stats show a trend in the right direction as an organisation. “The NHLS is committed to ensuring that the organisation Continues on page 12

INQABA BIOTEC Inqaba biotec is turning 20 years in 2022 and it all started on a bus ride from Sunnyside to the University of Pretoria in 2000. Due to the habit of taking the same bus in the morning, the two future co-founders Dr Joaquim de Gama (at that time still a law student) and Dr Oliver Preisig (a microbiology researcher at the university) got into regular conversations. Then one day Joaquim asks Oliver if they should not start a business to grow mushrooms. Oliver was enticed about the idea of a business but thought his experience could be more applicable for a company that offers DNA sequencing services and produces oligos. Such companies developed in many places in the 90s but none in South Africa or anywhere in Africa. So, the idea was born. Oliver shared the idea with some friends back home in Switzerland and Germany, and surprisingly the venture team of 5 was born with the addition of Prof Michael Göttfert, Dr Christoph Beck, and Dr Sandra Neumann. Of course, the four scientists and one lawyer had not much experience in writing a business plan and the first draft was a thick document that needed an astronomic amount of funds and guidance. We were then lucky to come across the Swiss Organisation to Facilitate Investments in the developing world (SOFI) and there we got support from a consultant, Mr Andre Calame, who coached us and assisted in the write-up of a concise and thorough business plan. He really was instrumental in the success of the company to get started as he took ownership of the project. With his advice, we applied for the Start-Up fund of the Swiss State Secretariat for Economic Affairs (seco) for business developments in developing countries in 2001. Luckily a pat-situation of the fund committee turned in our favour and we got a credit facility for CHF 250 000 despite the committee’s worries that we have no experience in marketing. With the credit letter from the Swiss Government, Standard Bank was willing to get us a lease funding for the lab equipment worth R 4 Million. As we know, banks only extend you a loan when you have collateral somewhere. In February 2002 we started occupying our first facility opposite the Sunnyside Police Station, where we even shared the floor with police detectives. In the first few months, we got everything installed, worked on the production of oligonucleotides and the optimisation of our Sanger sequencer. On August the 1st of 2002, we were ready to launch inqaba biotec with a very unique name that we found with the help of a Xhosa friend as we wanted to have a name with a click and of course a good meaning as well. And this is how Africa’s Genomics company started. Inqaba is an IsiXhosa name for “rare and precious” and pays homage to our South African origin. The company headquarter is still based in Pretoria, South Africa. In 2010 the Kenyan subsidiary, Inqaba Biotec East Africa Ltd, was launched in Nairobi. Thereafter, Inqaba Biotec West Africa Ltd was registered in Nigeria in the 2014 followed by branch offices in Ghana (2018), Tanzania (2019) and Senegal (2020). In 2007, inqaba biotec started offering genome sequencing using a sequencing technology from 454, which at that time was a novel innovation and made us pioneers in offering genome sequencing services in Africa. In 2020, we have started sequencing with the stateof-the-art sequencer Sequel IIe from PacBio. Currently, inqaba biotec employs over 100 people in South Africa, Ghana, Kenya, Mali, Nigeria, Senegal, Tanzania, Uganda and Zimbabwe creating a sales and support network across Sub-Saharan Africa. We also distribute a wide variety of reagents, instruments and solutions for molecular biology, molecular diagnostics. This will facilitate our aim of getting better support and logistics to our customers in the field of life sciences and molecular diagnostics as part of our contribution to further develop Science and Technology in sub-Saharan Africa.

10 / www.enterprise-africa.net

The Only One Tube You Need to LIVE WITH COVID-19 Allplex™ RV Master Assay is Seegene's comprehensive respiratory testing solution. Accurate and rapid identification of various major respiratory viruses (Flu A, Flu B, RSV, MPV, AdV, HRV and PIV), including SARS-CoV-2, enables appropriate prescription and response.

Respiratory symptoms

Test

Detection

Diagnosis

SARS-CoV-2 Flu A

Cough

Sore throat Runny nose

COVID-19

Flu B

Flu

RSV MPV

Common Cold

AdV

Pneumonia

HRV

Sneezing

PIV Fever

Pick & Match Solution Provides Superior Values Seegene’s Pick & Match Solution is for simultaneous detection and identification of SARS-CoV-2 and internationally spread variants. This smart solution will provide reliable COVID-19 test results for efficient infection control and patient care.

Complete Solution for SARS-CoV-2 & Its Variants

1 Test Solution for accurate SARS-CoV-2 screening and variants identification

Which SARS-CoV-2 Variants?

Variants

VII

- Alpha - Beta - Gamma - Omicron - Mu

Novaplex™ SARS-CoV-2 Variants VII Assay*

Variants

Allplex™ SARS-CoV-2 Variants II Assay

Streamlined Automated System

- Delta - Lamda - Mu

for high-throughput screening tests with less effort

Novaplex™ SARS-CoV-2 Variants VI Assay

Variants

- Delta - Lamda

Novaplex™ SARS-CoV-2 Variants V Assay

Variants

- Beta - Delta - Omicron

IT Solution - SG STATS for variant trend monitoring and variants analytic insights

Allplex™ SARS-CoV-2 Variants IV Assay

- Beta - Gamma - Delta - Omicron

Variants

- Alpha - Beta - Gamma - Omicron - Mu

Allplex™ SARS-CoV-2 Variants I Assay

Seegene Inc. Seoul, Republic of Korea Tel : +82-2-2240-4000 / E-mail : info@seegene.com

www.seegene.com Variants Assay

Inqaba Biotechnical Industries (Pty) Ltd Streamlined Automated System

Distributor for sub-Saharan Africa Tel : 012-343-5829 / E-mail: info@inqababiotec.co.za

www.inqababiotec.co.za

INDUSTRY FOCUS: HEALTHCARE

Continued from page 10 recognises and supports talent at all levels – from support functions to technical staff. The very nature of our diverse organisation means that colleagues develop at different times and require varying types of support and training throughout their careers,” she says. Chetty, who boasts more than two decades in senior management and lists human resource planning as a key skill, is clear that for those coming through the ranks continuous improvement is vital. “My advice to the younger generation, especially those in the NHLS, is that they must not limit themselves based on their technical expertise,” she asserts. “I want

12 / www.enterprise-africa.net

them to understand that learning something new is an investment in themselves, and adaptability is an asset that can help both individuals and organisations flourish. This is the reason we have a very efficient Workplace Skills Plan set out to promote and prioritise skills development in the organisation. We are doing this to capacitate and empower our workforce, especially the younger generation.”

// AT NHLS, WE ARE COMMITTED TO FOSTERING AN INCLUSIVE ENVIRONMENT WHERE EVERYONE CAN SUCCEED //

FUTURE PROGNOSIS While the Covid-19 pandemic and the consequent fear of serious illness or death among the population remains, for many, life does begin to return to normal with offices and factories welcoming staff back after the 21/22 festive period. But testing for positive

cases will continue and for most in healthcare the expectation is that this will form a long-term part of strategy to live with the virus. The NHLS will assist government in planning for the future while continuing to roll out its pathology services in the arenas of TB, HIV and others. It is a time where the

NATIONAL HEALTH LABORATORY SERVICE

True sample-to-result automation Increase lab productivity and efficiency Flexibility with no batching restrictions

Real time Quality assurance with iQM2 Advanced simplicity Custom connectivity allows complete control

Tel: +27 (0)11 804 4004 | sales@ilex.co.za | www.ilex.co.za

// MY ADVICE TO THE YOUNGER GENERATION, ESPECIALLY THOSE IN THE NHLS, IS THAT THEY MUST NOT LIMIT THEMSELVES BASED ON THEIR TECHNICAL EXPERTISE // business must adapt and grow, and Chetty is confident. “In the next five years, the NHLS will, inter alia, focus on providing a clinically accepted diagnostic pathology service, high-quality patient-centred pathology service at the right time and the right place, deliver value in pathology services through improved cost-effectiveness, and leverage innovation and new technology to improve efficiency. “We will also invest in information, digital technology, communication links and logistical

services to improve efficiency.” With another ongoing planning challenge – the onset of National Health Insurance (NHI) – constant reviews and strategy adjustments must be made. It’s no easy task. “The NHLS is a national asset and is well-positioned for NHI,” Chetty enthuses. “It is a single, national organisation, that provides pathology services to every public sector clinic and hospital across the country. It is against this backdrop that the organisation strives to provide highquality pathology and laboratory

services that are clinically efficient and cost-effective.” Of course, the CEO is also working towards strengthening and maintaining the NHLS financial standing, and improving operational efficiencies, accreditation of laboratories, while making enhancements to IT infrastructure. For most, with a dramatic shift in focus, and the need to adapt from one day to the next, the NHLS has continued to provide service of the highest order during the most difficult conditions witnessed through its history. The company has proven its value to the nation and continues to show its significance as a SOE.

WWW.NHLS.AC.ZA

www.enterprise-africa.net / 13

CMB Media Group does not accept responsibility for omissions or errors. The points of view expressed in articles by attributing writers and/ or in advertisements included in this magazine do not necessarily represent those of the publisher. Any resemblance to real persons, living or dead is purely coincidental. Whilst every effort is made to ensure the accuracy of the information contained within this magazine, no legal responsibility will be accepted by the publishers for loss arising from use of information published. All rights reserved. No part of this publication may be reproduced or stored in a retrievable system or transmitted in any form or by any means without the prior written consent of the publisher. © CMB Media Group Ltd 2022

THE BUSINESS MAGAZINE FOR AFRICA’S INDUSTRY LEADERS

AFRICA

Published by CMB Media Group Chris Bolderstone – General Manager chris@cmb-media.co.uk Kiln House, Fuel Studios, Pottergate, Norwich NR2 1DX T. +44 (0) 1603 855 161 E. info@cmb-media.co.uk www.cmb-media.co.uk

February 2022

www.enterprise-africa.net

Gondwana Sees Light at the End of Dark Tunnel Exclusive interview with Gys Joubert, Gondwana Collection’s Managing Director

ALSO IN THIS ISSUE:

BitCo Telecoms / Carrick Wealth / National Flag / NHLS

AS FEAT UR ED IN

ENTERPRISE AFRICA

FEBR UAR Y 2022